Post-marketing Surveillance Protocol Number; CABL001A1401

Special drug use-results surveillance of Scemblix Tablets(resistant or intolerant chronic myeloid leukemia)

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031220191

Enrollment

440

Registered

2022-07-07

Start date

2022-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic myeloid leukemia resistant or intolerant to pretreatment drugs

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients treated with asciminib

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
To assess the safety profile of the safety specifications (myelosuppression, infections, QT interval prolongation, pancreatitis, vascular occlusive events, photosensitivity)	—

Contacts

Public ContactNovartis Direct

Novartis Pharma. K.K.

sm.pms@novartis.com+81-120003293

Outcome results